Related Experiment Video
Updated: Jul 5, 2026
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens
1Division of Hematologic Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Abstract:
FMS-Like-Tyrosine kinase-3 (FLT3) mutations are found in about 30% of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival. Targeting of this tyrosine kinase by direction inhibition is the focus of both preclinical and clinical research in AML. Several molecules in clinical development inhibit FLT3 with varying degrees of specificity. Preclinical models suggest that these compounds enhance the cytotoxicity of conventional chemotherapeutics against FLT3 mutant leukemia cells. The pharmacodynamic interactions between FLT3 inhibitors and chemotherapy appear to be sequence dependent. When the FLT3 inhibitor is used prior to chemotherapy, antagonism is displayed, while if FLT3 inhibition is instituted after to exposure to chemotherapy, synergistic cytotoxicity is seen. The combination of FLT3 inhibitors with chemotherapy is also complicated by potential pharmacokinetic obstacles, such as plasma protein binding and p-glycoprotein interactions. Ongoing and future studies are aimed at incorporating FLT3 inhibitors into conventional induction and consolidation therapy specifically for patients with FLT3 mutant AML.
Insights
Targeting FMS-Like-Tyrosine kinase-3 (FLT3) mutations in acute myeloid leukemia (AML) with inhibitors shows promise. Optimal sequencing with chemotherapy is crucial for synergistic effects and improved patient outcomes.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- FMS-Like-Tyrosine kinase-3 (FLT3) mutations occur in ~30% of acute myeloid leukemia (AML) cases.
- These mutations are associated with higher relapse rates and poorer survival.
- Targeting FLT3 is a key strategy in AML research.
Purpose of the Study:
- To investigate the efficacy of FLT3 inhibitors in AML.
- To explore the pharmacodynamic interactions between FLT3 inhibitors and conventional chemotherapy.
- To inform the development of combination therapies for FLT3-mutated AML.
Main Methods:
- Preclinical models of FLT3-mutated AML.
- Evaluation of FLT3 inhibitors alone and in combination with chemotherapy.
- Assessment of cytotoxicity and sequence-dependent effects.
Main Results:
- FLT3 inhibitors enhance chemotherapy cytotoxicity against FLT3-mutated leukemia cells.
- Synergistic cytotoxicity is observed when FLT3 inhibition follows chemotherapy exposure.
- Antagonistic effects occur when FLT3 inhibitors precede chemotherapy.
Conclusions:
- The sequence of administration is critical for the efficacy of FLT3 inhibitors combined with chemotherapy.
- Pharmacokinetic challenges like protein binding and p-glycoprotein interactions need consideration.
- Future studies will focus on integrating FLT3 inhibitors into AML treatment regimens for FLT3-mutated patients.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...